Patents by Inventor Mahesh Kandula

Mahesh Kandula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210171564
    Abstract: The compositions and compounds of formula I and formula II which includes nucleic acid synthesis inhibitor conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of cancer or its associated complications.
    Type: Application
    Filed: July 9, 2019
    Publication date: June 10, 2021
    Applicant: Cellix Bio Provate Limited
    Inventor: Mahesh Kandula
  • Patent number: 11000487
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV and the methods for the treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: May 11, 2021
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Publication number: 20210078983
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII and, the methods for the treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases.
    Type: Application
    Filed: September 30, 2020
    Publication date: March 18, 2021
    Applicant: Cellix Bio Provate Limited
    Inventor: Mahesh Kandula
  • Patent number: 10933052
    Abstract: Aspects of the present disclosure provide compound of Formula I and pharmaceutically acceptable hydrates, solvates, crystals, co-crystals, enantiomers, stereoisomers, polymorphs and prodrugs thereof that can find utility in treatment of eye disorders and complications associated therewith. Aspects of the present disclosure also relate to methods of treating an eye disorder and/or complications thereof in a subject in need thereof by administering the compound of Formula I or a pharmaceutically acceptable hydrate, solvate, crystal, enantiomer, stereoisomer, polymorph or prodrug thereof.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: March 2, 2021
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Publication number: 20210053950
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.
    Type: Application
    Filed: October 8, 2020
    Publication date: February 25, 2021
    Applicant: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Publication number: 20210032194
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III and the methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases.
    Type: Application
    Filed: October 18, 2020
    Publication date: February 4, 2021
    Applicant: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Patent number: 10858349
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII and, the methods for the treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: December 8, 2020
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Publication number: 20200375961
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof. The antimuscarinic or anticholinergic agent is a compound of Formula I, Formula II, or Formula III and lipoic acid is a compound of Formula IV or Formula V. The Pharmaceutical composition is a physical mixture of an antimuscarinic or an anticholinergic agent and lipoic acid.
    Type: Application
    Filed: August 4, 2020
    Publication date: December 3, 2020
    Inventor: Mahesh Kandula
  • Publication number: 20200361912
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.
    Type: Application
    Filed: November 24, 2017
    Publication date: November 19, 2020
    Applicant: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Publication number: 20200361874
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.
    Type: Application
    Filed: April 19, 2017
    Publication date: November 19, 2020
    Applicant: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 10829454
    Abstract: The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III, and methods for treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's disease such as Parkinson's disease, scleroderma, restless leg syndrome, hypertension and gestational hypertension.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: November 10, 2020
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Patent number: 10774059
    Abstract: The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: September 15, 2020
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Publication number: 20200262809
    Abstract: Disclosed is a compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof, which is useful for treatment of eye disorders, skin diseases and/or complications associated therewith. Also disclosed is a pharmaceutical composition comprising as an active ingredient at least one compound of formula I and a pharmaceutically acceptable excipient. Also disclosed is a method of treating an eye disorder, skin disease and/or a complication thereof in a subject in need thereof by administering at least one compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 20, 2020
    Inventor: Mahesh Kandula
  • Publication number: 20200190040
    Abstract: The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V and formula VI or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications.
    Type: Application
    Filed: April 19, 2017
    Publication date: June 18, 2020
    Applicant: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Publication number: 20200179343
    Abstract: Aspects of the present disclosure provide compound of Formula I and pharmaceutically acceptable hydrates, solvates, crystals, co-crystals, enantiomers, stereoisomers, polymorphs and prodrugs thereof that can find utility in treatment of eye disorders and complications associated therewith. Aspects of the present disclosure also relate to methods of treating an eye disorder and/or complications thereof in a subject in need thereof by administering the compound of Formula I or a pharmaceutically acceptable hydrate, solvate, crystal, enantiomer, stereoisomer, polymorph or prodrug thereof.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 11, 2020
    Inventor: Mahesh Kandula
  • Publication number: 20200040003
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV and formula V and the methods for the treatment of xerostomia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases.
    Type: Application
    Filed: April 19, 2017
    Publication date: February 6, 2020
    Inventor: Mahesh Kandula
  • Publication number: 20190382364
    Abstract: The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications.
    Type: Application
    Filed: June 19, 2019
    Publication date: December 19, 2019
    Inventor: Mahesh Kandula
  • Publication number: 20190350877
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV and the methods for the treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain.
    Type: Application
    Filed: April 19, 2017
    Publication date: November 21, 2019
    Applicant: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Publication number: 20190292171
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII and, the methods for the treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases.
    Type: Application
    Filed: May 12, 2017
    Publication date: September 26, 2019
    Applicant: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 10343994
    Abstract: The invention relates to the compounds of formula I, formula II, formula III, formula IV and formula V or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV or formula V and methods for the treatment of inflammation and pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of pain, oral mucosal inflammatory or oral infectious diseases.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: July 9, 2019
    Inventor: Mahesh Kandula